leisure time -WSS

leisure time

author：hotspot 2025-10-01 21:36:48 - browse：45456

insulin biosimilar — The suit, filed in a Texas federal court by the American Clinical Laboratory Association and PCR lab HealthTrackRx, claims the FDA does not have the authority to scrutinize lab-developed tests. Jacquelyn Martin/AP

A group representing clinical labs across the country sued the Food and Drug Administration on Wednesday over the agency’s plan to actively regulate lab-developed tests.

The suit, filed in a Texas federal court by the American Clinical Laboratory Association and PCR lab HealthTrackRx, claims the FDA does not have the authority to scrutinize lab-developed tests. When the FDA finalized its test regulation plan last month, several experts said it was only a matter of time until someone in the lab industry sued.

Tests made in labs have historically gone unregulated by the FDA, as the agency considered them low-risk when it started regulating medical devices in 1976. But the tests have since become more numerous and complex, and the regulatory gray area enabled unreliable tests to thrive and harm patients. Infamous examples include Theranos’ blood tests, as well as misleading prenatal genetic tests from a range of companies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Is mRNA technology the right fit for flu shots? Experts aren’t so sure

WSS

Despite FDA concern, risk that CAR

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

Trump got a 'target letter.' What is one and what does it mean?

Stanford president to resign after investigation of research

30 years of 'Listening to Prozac'

Fetal surgery at risk from Dobbs and new abortion restrictions

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

leisure time

As demand for Covid shots wanes, Moderna seeks its next success

Pediatric cancer treatments threatened by a new FDA policy

Anesthesiologist group: stop taking Ozempic before surgery

Flagship Pioneering launches a new biotech in two countries

Psychedelics group wrestles with new pharma identity

Will the market for weight loss drugs really reach $100 billion?

Activists slam private health insurers over coverage restrictions

J&J to emphasize cancer drugs, stop much of its vaccine research

As demand for Covid shots wanes, Moderna seeks its next success

Diagnostic tests are hitting their mathematical limits

knowledge

Stanford president to resign after investigation of research

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

Lindsay Lohan welcomes 1st child with husband Bader Shammas

India sets sights on home

FDA investigates CAR

Takeda, Janssen join wearable maker to measure scratching

hotspot

Wikipedia

knowledge

knowledge